McKesson closes RxCrossroads deal
McKesson on Wednesday completed its previously announced acquisition of RxCrossroads. RxCrossroads has become a part of the company’s McKesson Specialty Health business.
According to the wholesaler, the acquisition is expected to enhance McKesson’s existing commercialization solutions for manufacturers of branded, specialty, generic and biosimilar drugs, including comprehensive patient support (“hub”) services, custom pharmacy solutions and third-party logistics, allowing McKesson to grow its end-to-end offerings for manufacturers.
In addition, the acquisition adds plasma logistics to McKesson’s manufacturer services, complementing the company’s established customer-facing plasma offerings.
Originally announced in November, McKesson purchased RxCrossroads from CVS Health in a deal valued at $735 million.